News

News2025-07-02T17:16:16-04:00

HMS in the News

805, 2025

Research Article: Science & Society

May 8, 2025|

In "Beyond the lab: trust, storytelling and the fight for America's attention," authors Aaron F. Mertz, executive director of Science & Society at the Aspen Institute, and Shruti Naik, associate professor at Icahn School of Medicine at Mt. Sinai, [read more]

505, 2025

Announcement: Launching the Neuroarts Resource Center

May 5, 2025|

The Neuroarts Resource Center offers a comprehensive and continually updated collection of neuroarts-related resources, including the latest research, best practices, funding opportunities, and career postings. Its fully indexed and searchable interface allows users to easily find the information they [read more]

306, 2024

Press Release: NeuroArts Blueprint Initiative

June 3, 2024|

NeuroArts Blueprint The Music Man Foundation today announced a $1 million award to the NeuroArts Blueprint Initiative to catalyze the research, practice, policy, and culture changes necessary to sustain the field of neuroarts. Neuroarts is the study of [read more]

Recent Releases

902, 2023

A Blueprint for Equitable AI

February 9, 2023|

Science & Society

The Science & Society Program convened two diverse groups of cross-sector experts to discuss how they would advise building and distributing artificial intelligence for equitable outcomes, and summarized the discussions in a publicly available report, A Blueprint for Equitable AI.

1110, 2022

In Favor of Pure Science

October 11, 2022|

Science & Society

This Science & Society report, In Favor of Pure Science, assesses the current state of basic science around the world, creates a forum for discussion among scientific leaders, and provides guidance on how basic science can be supported and advanced internationally. It was developed in collaboration with Aspen Institute international partners in 13 countries.

2208, 2022

Talking Health: A New Way to Communicate About Public Health

August 22, 2022|

PHRASES

Public Health Reaching Across Sectors (PHRASES), an initiative jointly launched by the de Beaumont Foundation and HMS, informed and inspired Talking Health, published by Oxford University Press. Ruth Katz, HMS executive director, co-authored the introduction to the book, which builds on the recognition that public health needs to tell its story more effectively. Talking Health offers resources to help public health professionals better communicate about the role and value of their field and form stronger cross-sector partnerships.

1905, 2022

Budgeting for Disease Prevention and Health Promotion: Improving the Federal Scorekeeping Process

May 19, 2022|

Health, Medicine & Society

This report highlights consensus recommendations emerging from an HMS convening that brought together former Congressional Budget Office (CBO) and Office of Management and Budget leaders. Their conclusion: Structural changes to current federal costing and scorekeeping practices could clarify the value of clinical and population-level programs that elevate health through prevention activities. Dan Crippen, former CBO director and former executive director of the National Governors Association, and Nancy-Ann DeParle, former director of White House Office of Health Reform during the Obama Administration, chaired the group.

804, 2022

Reducing the Health Harms of Incarceration

April 8, 2022|

Aspen Health Strategy Group

This Aspen Health Strategy Group report offers five big ideas for tackling systemic issues at the intersection of incarceration and health. Action steps to reduce the harm: repeal the Medicaid exclusion for this population, prioritize health in correctional systems, upgrade quality standards of carceral health, coordinate care within and outside carceral settings, and dramatically reduce the level and consequences of incarceration. Background papers provide a fuller context for these ideas.

2402, 2022

Breakthrough Cures, Blockbuster Costs: Future Directions

February 24, 2022|

Health, Medicine & Society

Published by Blue Cross Blue Shield Association and HMS, this report examines advanced therapies—biomedical breakthroughs that often treat rare conditions and can transform or even save a patient’s life—that tend to come with extremely high price tags. By 2031, as many as 90 gene and cellular therapies are expected to be approved for use by 550,000 patients, at an annual acquisition cost of $30 billion. A framework for ensuring that high-cost medicines for rare conditions are affordable and accessible to patients emerged from a convening co-chaired by two former U.S. Food and Drug Administration (FDA) commissioners, Scott Gottlieb and Margaret Hamburg.

Go to Top